Compare VERX & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERX | LQDA |
|---|---|---|
| Founded | 1978 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2020 | 2018 |
| Metric | VERX | LQDA |
|---|---|---|
| Price | $19.93 | $35.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | $35.73 | ★ $37.40 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 02-26-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $732,189,000.00 | $69,216,000.00 |
| Revenue This Year | $14.49 | $994.17 |
| Revenue Next Year | $10.82 | $169.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.83 | ★ 343.41 |
| 52 Week Low | $18.54 | $11.26 |
| 52 Week High | $60.71 | $38.16 |
| Indicator | VERX | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 59.65 |
| Support Level | $18.93 | $29.30 |
| Resistance Level | $20.40 | $35.20 |
| Average True Range (ATR) | 0.59 | 2.26 |
| MACD | 0.04 | -0.36 |
| Stochastic Oscillator | 56.50 | 71.95 |
Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. Vertex provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting among others. The company derives revenue from software subscriptions.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.